Groundbreaking Skin Treatment Shows 100% Response Rate

ENV-294 Delivers Exceptional Results for Severe Eczema Patients

In remarkable Phase 1b trial results that have surprised even researchers, Enveda's experimental treatment ENV-294 achieved a 100% response rate in patients with moderate to severe atopic dermatitis — a condition that affects millions worldwide and has historically been difficult to treat effectively.

The results exceeded all expectations: every single patient achieved at least 50% improvement in their Eczema Area and Severity Index (EASI-50), with 78% reaching 75% improvement and 56% achieving 90% improvement. Perhaps most encouraging of all, patients continued to benefit even after treatment stopped, suggesting lasting therapeutic effects.

For patients with severe atopic dermatitis, this represents a potential game-changer. Current treatments often provide only modest relief, leaving many patients struggling with painful, itchy lesions that significantly impact quality of life, sleep, and mental health.

The favorable safety profile observed in the trial adds to the optimism surrounding this potential breakthrough treatment.

Key Facts

• Key Facts & Figures
  • 100% of patients achieved EASI-50 improvement (50% symptom reduction) — Enveda trial data
• 78% achieved EASI-75 improvement (75% symptom reduction) — Enveda trial data
• 56% reached EASI-90 improvement (90% symptom reduction) — Enveda trial data
• Benefits continued after treatment cessation — clinical observation
• Favorable safety profile reported across all patients